autologous dendritic cells pulsed with antigen peptides

Autologous dendritic cells pulsed with antigen peptides are a form of **cell therapy** in which dendritic cells, derived from the patient's own peripheral blood, are exposed ex vivo to defined antigenic peptides, typically tumor-associated antigens or personalized neoantigens, and then administered back to the patient. These peptide-pulsed dendritic cells are intended to efficiently present the loaded antigens to T cells, particularly cytotoxic T lymphocytes (CTLs), priming them to target and eliminate antigen-expressing tumor cells or pathogens. This approach is most often explored as a personalized therapeutic cancer vaccine, with applications reported in a range of solid tumors (such as melanoma, glioblastoma, lung, renal, and hepatocellular carcinomas). The immune response elicited is predominantly cellular, often involving TH1/TH17 responses and antigen-specific CTLs. Multiple studies indicate a favorable safety profile and the potential for clinical benefit, though efficacy is still being established in clinical trials[1][2][3][4].

Other names

autologous peptide-pulsed dendritic cellsautologous peptide-loaded dendritic cellsautologous dendritic cell vaccine pulsed with antigen peptides